Summary The proliferative potential of human solid tumours, in vivo, was investigated using bromodeoxyuridine (BrdUrd) incorporation and flow cytometry (FCM). Patients with solid tumours from a variety of sites were injected with 500mg BrdUrd, intravenously, several hours prior to biopsy or surgical excision. The labelling index (LI), duration of S-phase (Ts) and thus the potential doubling time (Tpot) could be measured within 24h of sampling. The results show that both the LI The cellular proliferation of human cancer has been the subject of much study over the years, aimed at rationalising treatment so that schedules more suited to the cell kinetic characteristics of individual tumours can be given. However, progress has been hampered by the nature of the techniques available to measure cell kinetic parameters. The incidence of mitotic figures has been used to relate cell production rate to histological parameters and patient survival (Weiss, 1971) . However, this parameter has failed to demonstrate any significant correlation with survival. The stathmokinetic method has been applied to human tumours by several groups (Meyer & Donaldson, 1969; Camplejohn et al., 1973) to overcome the inadequacies of mitotic index alone. However, it is not possible to ensure that maximum mitotic collection rate is achieved. The most widely used method has been to measure the labelling index using tritiated thymidine (3HTdR) and autoradiography. The bulk of the data obtained using this method have come from labelling tumour explants or cell suspensions in vitro (see Steel, 1977; Meyer, 1982 for reviews). Some studies have been performed in vivo (Frindel & Tubiana, 1968; Bennington, 1969; Young & DeVita, 1970; Terz et al., 1971; Bresciani et al., 1974) . However, the technique suffers from two major drawbacks. Firstly, the result is not achieved in a time-scale suitable for the clinician to use if treatment is to be based on cell kinetic characteristics. Secondly, its wide use in vivo is precluded due to ethical considerations involved in administering a radioactive precursor of DNA and the requirement for multiple biopsies if cell cycle measurements are to be made.
The cellular proliferation of human cancer has been the subject of much study over the years, aimed at rationalising treatment so that schedules more suited to the cell kinetic characteristics of individual tumours can be given. However, progress has been hampered by the nature of the techniques available to measure cell kinetic parameters. The incidence of mitotic figures has been used to relate cell production rate to histological parameters and patient survival (Weiss, 1971) . However, this parameter has failed to demonstrate any significant correlation with survival. The stathmokinetic method has been applied to human tumours by several groups (Meyer & Donaldson, 1969; Camplejohn et al., 1973) to overcome the inadequacies of mitotic index alone. However, it is not possible to ensure that maximum mitotic collection rate is achieved. The most widely used method has been to measure the labelling index using tritiated thymidine (3HTdR) and autoradiography. The bulk of the data obtained using this method have come from labelling tumour explants or cell suspensions in vitro (see Steel, 1977; Meyer, 1982 for reviews) . Some studies have been performed in vivo (Frindel & Tubiana, 1968; Bennington, 1969; Young & DeVita, 1970; Terz et al., 1971; Bresciani et al., 1974) . However, the technique suffers from two major drawbacks. Firstly, the result is not achieved in a time-scale suitable for the clinician to use if treatment is to be based on cell kinetic characteristics. Secondly, its wide use in vivo is precluded due to ethical considerations involved in administering a radioactive precursor of DNA and the requirement for multiple biopsies if cell cycle measurements are to be made.
A technique which allows cell kinetic measurements to be made on individual human tumours in a time-scale of use to the clinician in planning the most appropriate treatment, is that based on the flow cytometric measurement of bromodeoxyuridine (BrdUrd) incorporation into DNA (Gratzner, 1982; Dolbeare et al., 1983) . We have previously shown that it is possible to measure the labelling index (LI) of human tumours following an in vivo injection of BrdUrd, and using mouse tumours have shown that the BrdUrd technique gives the same information as the use of 3HTdR (Wilson et al., 1985) . The principal advantages of this flow cytometric technique are that it is rapid (the result can be obtained within a day of surgery), it not radioactive or toxic at the doses required for cell kinetic studies, and it is possible to estimate both the LI and the duration of S-phase (Ts) and hence the potential doubling time (Tpot) from a single biopsy. The technique to estimate Tpot is based on the procedure first described by Begg et al. (1985) , whereby a biopsy is taken several hours after an i.v. injection of BrdUrd.
In this study we describe results of measurements of Tpot in 26 patients with a variety of solid tumours and show that the method is applicable to routine measurements of cell kinetics in human tumours. In addition, we address the problem of heterogeneity in human tumours by studying multiple samples in four of the patients.
Materials and methods
Patient selection Permission to administer BrdUrd was granted by the Ethical Committee of Mount Vernon Hospital and informed consent was obtained from each patient. The study included a spectrum of tumours, both primary and secondary, from the cervix, rectum, oesophagus, bronchus, head and neck and two melanomas (see Table I ).
BrdUrd adninistration BrdUrd suitable for in vivo administration to humans was obtained from the Investigational Drug Division of the National Institute of Health, Bethesda, Maryland. Immediately prior to injection 500mg BrdUrd was dissolved in 100ml 0.9% saline and administered by intravenous infusion over 30min (in our most recent studies the dose of BrdUrd has been reduced to 200mg and is administered as a single push in 20ml normal saline). A biopsy or surgical excision was performed in each case between 4 and 22 h after injection (most were taken between 4 and 8 h). No toxicity was observed in any patient given 500mg BrdUrd in this manner. In all cases an adjacent portion of material was examined histologically so that the proportion of the specimen occupied by tumour cells, stroma and necrosis could be estimated.
Cell preparation
The tumours were processed into single cells by a variety of Br. J. Cancer (1988), 58, 423-431 methods depending on the nature of the material. The procedures have been described in detail elsewhere (Wilson et al., 1985 (Schutte et al., 1987) .
BrdUrd staining and flow cytometry The procedures for BrdUrd staining and FCM analysis have been described in detail previously (Wilson et al., 1985 Cytofluorograph with excitation at 488nm (1OOmW) from a 5W argon ion laser. Green fluorescence (FITC) was collected between 510-560nm and red fluorescence (PI) above 620 nm. Data were collected in list mode and cell doublets, triplets etc., were excluded from the analysis by gating on the DNA peak versus area signal. 10,000 to 50,000 cells were analysed for each specimen. Table I shows the clinical and histopathological details of the patients involved in this study. The series included a spectrum of both primary, recurrent and metastatic tumours from different sites. Fourteen of the tumours were squamous cell carcinomas and 6 were adenocarcinomas. The largest series from an individual site were nine head and neck tumours (group E). Figures I and 2 show examples of the staining profiles obtained several hours after administration of BrdUrd to patients with solid tumours. Figure lA shows the DNA profile and 1 B the bivariate cytogram of DNA content versus BrdUrd uptake for a moderately differentiated adenocarcinoma of the rectum removed 5.5h after injection of BrdUrd (patient Cl in Table I ). The tumour was aneuploid ( Figure IA) with a DNA index of 1.6. The hyperdiploid component (i.e. those cells with greater than 2n DNA content) represented 73% of the total cell population. The bivariate cytogram (Figure 1 B) number of BrdUrd labelled cells which had divided (both in the diploid and the aneuploid populations) and subtract half of this number from the total number of labelled cells and from the total number of cells. This, however, may lead to an underestimation of the true LI as it does not take into account unlabelled G2 cells which will also have divided and expanded the cell population at the time of biopsy. If it were also possible to estimate the number of G2 cells which had divided then a better estimate of the true LI could be made. However this is not possible because the unlabelled cells in GI at the time of biopsy will be a mixture of cells that were in GI at the time of labelling that have not yet progressed into S and G2 cells that have divided. Consequently, we have corrected the LI simply by halving the number of labelled cells which have divided. This correction reduces the LI to 12.4 and 16.0% in the total cell and hyperdiploid only populations, respectively, in Figure IB . The estimation of Ts from profiles such as this was made using the technique described by Begg et al. (1985) . In this analysis the mean DNA content of the BrdUrd labelled cells still progressing through S-phase (i.e. those cells in the rectangular region) is expressed as a proportion of the difference in DNA content between Gl and G2+M cells. This is achieved by measuring the mean DNA content of GI and G2 + M cells either from the bivariate cytogram or the DNA profile and the mean DNA content of the BrdUrd labelled cells which are still progressing through S and have not yet divided. The 'relative movement' (R.M.) is then calculated by subtracting the mean DNA of Gl cells from that of the S-phase population and dividing it by the GI DNA content subtracted from the G2 DNA content. In order to make the calculation of Ts from the R.M., three assumptions are made: firstly, that immediately after injection with BrdUrd, the labelled S-phase cells are evenly distributed throughout S-phase with a mean DNA content in mid-S, giving a relative movement of 0.5; secondly, that the R.M. reaches 1.0 when those labelled cells that had just entered S-phase reach G2; i.e. in a time equal to Ts; thirdly, that the R.M. is a linear function of time. It is then possible to calculate Ts from a single measurement of R.M. at some time after pulse labelling with BrdUrd. In Figure lB the R.M. was 0.61 giving a Ts of 25.8 h. Using this value and the LI of 16.0%, the potential doubling time (Tpot) can be calculated from the relationship; Tpot=A. Ts/ LI, where A is a correction factor for the age distribution of the population. A value of 0.8 was used in these calculations (see Steel, 1977) , giving a Tpot of 5.4 days in this tumour. Figure 2 shows the profiles obtained from a malignant melanoma biopsied 7 h after BrdUrd injection (Patient II in Table I ). The DNA profile ( Figure 2A ) shows that the cell population was diploid. The striking feature of this specimen was that the majority of BrdUrd labelled cells: had divided and entered GI in 7 h. The Ts measurement gave a value of 8.8 h and this, in conjunction with a corrected LI of 8.3%, gave a Tpot of 3.2 days. This is extremely short, implying very rapid proliferation in this tumour. then 13 patients would have been wrongly classified into the 'rapid' or 'slow' proliferating groups. Eight of these were patients whose tumours had LIs less than 10% but Tpots of less than 5 days; the other five had high LIs but longer Tpots. Figure 5B shows that the situation was only slightly improved when the aneuploid LI was used, where it was measurable. Five patients remained in the low LI short Tpot group and 5 in the higher LI long Tpot group. All 4 cases of rectal carcinoma fell into the group of high LI but long Tpot whilst 4 cases of head and neck tumours were found in the low LI short Tpot group. This demonstrates the dependence of Tpot on Ts. Any procedure which is based upon measurements from a single small biopsy suffers from the criticism that the biopsy may not be representative of the whole tumour. We have addressed this problem in four of the tumours, in which it was possible to take several samples. Figure 6 shows the results obtained for patient B3. The specimens consisted of four samples selected at random by the pathologist from a large surgically resected tumour of the cervix; histologically the four pieces all contained anaplastic squamous carcinoma cells but there were differences in the amount of stromal and of necrotic areas. Figure 6a shows the relative amounts of tumour, stroma and necrosis in each sample, estimated histologically, and should be compared with Figure the diploid Gl) showed less variation (Figure 6d) , with a mean of 11.0+0.9%. There was very little difference in the estimate of Ts between the samples (range 10.5 to 12 h) (Figure 6e ) with the result that the variation in the calculated potential doubling time reflected, primarily, variations in the LI between samples. This ranged from 2.9 to 4.6 days with a mean of 3.6 + 0.4 days (Figure 6f ). There was no change in the DNA index between the samples (results not shown). Figure 7 shows results obtained in patient C4. This patient had previously undergone a resection and anastomosis for carcinoma of the rectum. The specimens removed for this study came from a recurrence in the rectal stump. Four areas of the tumour were sampled as was a polypoid fragment. All samples, including the tissue from the polypoid region, showed similar histology with presence of a moderately differentiated and partly mucin secreting adenocarcinoma similar to the primary. The DNA content of the specimens was diploid. In this patient, there was variation in both the LI (Figure 7a ) and Ts ( Figure 7b ) and, hence, the Tpot (Figure 7c ) measurements between the individual samples. The LI ranged from 8.9 to 13.1% and the Ts from 13 to 19 h in the biopsies from the main tumour area which resulted in a range of Tpot of 3.4 to 6.9 days. The cell kinetic characteristics of the tumour tissue from the polypoid area was markedly different to the other samples; the LI was 8.7% and the Ts 31.9h giving a Tpot of 12.2 days.
Results
The other two patients, D4 and H1, did not show any significant difference in cell kinetic parameters between different biopsies. Six biopsies were processed from patient H1; all 6 showed similar histology with the presence of diffuse grade II non-Hodgkin's lymphoma. The tumour was diploid and the LI and Ts ranged from 2.2 to 2.5% and 14.7 to 16.7h, respectively. The estimates of Tpot ranged from 21.3 to 25.3 days (Figure 8 ). Patient D4, had a poorly differentiated infiltrating SCC of the oesophagus which extended to the surrounding connective tissue. Two areas were studied, one sample was taken from the lumen surface and the other from the area infiltrating the connective tissue; these specimens showed similar histology. The tumour was aneuploid, but there were no significant differences in DNA index, % of hyperdiploid cells, total LI, aneuploid LI, Ts or Tpot (Figure 9 ).
Discussion
This study demonstrates the feasibility of making routine measurements of cell kinetics in solid human tumours using BrdUrd administration and FCM. The technique offers obvious advantages over previous techniques using 3HTdR and autoradiography. Labelling can be done in vivo without the problems associated with the administration of radioactive material to patients or multiple sampling. BrdUrd is non-toxic at the dose (500mg) used in these studies, and we have recently reduced this dose to 200mg without any loss of resolution of the BrdUrd profiles; doses as high as 1,000 mg m-2 day -for up to 2 weeks have been administered to patients in radiosensitization studies with no acute toxicity (Kinsella et al., 1984) . In addition, the results can be obtained within a day.
Ten patients who were administered BrdUrd failed to give a satisfactory result (data not shown). However, in 7 of the cases that failed there were too few viable cells in the biopsy either because of extensive necrosis or the biopsy was too small to give sufficient cells for FCM (at least I million cells at the start of staining are required). There were 3 cases in which the BrdUrd staining failed for no apparent reason.
The parameters that can be measured from a single biopsy are the LI, Ts and thus Tpot. The potential doubling time is the doubling time of a population of cells taking into account the growth fraction but ignoring cell loss. There is evidence in both animal and human tumours that repopulation rates during or after radiotherapy are similar to the potential doubling time. Maciejewski et al.. (1983) showed that local control of T3/4 larynx cancer fell from acceptable levels when the overall treatment time was extended beyond 6 weeks. The dose to control 50% of the tumours increased by about 0.5 Gy per day which is consistent with a population doubling time of about 4 days. This is similar to (1) and an area infiltrating the connective tissue (2). (Trott & K (1980) (Terz (Shirakawa et al., 1970 Kaser, 1972 11.5%. They showed that in 10 of the tumours there was reasonable agreement between the two methods but that ,orrected TPOT (days) there was serious underestimation of LI by in vitro labelling ed in LI (a) and Tpot (b) if correction in the other 6 tumours. The overall conclusion, from their labelled cells between injection and study, was that in vitro techniques may lead to an underestimation of LI due either to heterogeneity from one biopsy to another in the same tumour or a lower uptake of DNA precursor in the deep cell layers of the in vitro labelled ime of the untreated tumours calcutumour fragments. If heterogeneity was the problem, then 3HTdR LI of 15% observed in one might have expected the variation between in vivo and in as of the head and neck, assuming a vitro LI to have been more random. This data and our own ummermehr, 1985). Parsons et al. data suggests that in vitro labelling is underestimating the al control and 5 year survival, for true labelling index. This study and our previous study neck cancer, improved if 30 fractions (Wilson et al., 1985) have demonstrated the presence of a ,ompared to 30 fractions in 8 weeks significant proportion of S-phase cells which do not appear the middle. An average improvement to take up BrdUrd. In this study we are not able to estimate cal control for all stages of disease.
the relative proportions of these two populations as we are increase in effective dose and an delaying the biopsy after injection such that at the time we :11 kill. This corresponds to at least 3 make our observation there will be cells in S-phase which do ier in 2 weeks (Fowler, 1985) . This not show BrdUrd uptake because they were in GI at the ' the value of Tpot mentioned above.
time of the injection. It is apparent that this population of S-.tion rates of human tumours can be phase cells varies from tumour to tumour and can be as time to local recurrence after potensmall as only a few percent of the total S-phase population apy (Thames et al., 1983) , assuming or can be as great as 50%. The identity and significance of of uncontrolled tumours starts from these cells has yet to be established. The lack of BrdUrd nic cells. Using this approach, Trott uptake might be due to failure to be exposed to the DNA showed that the tumour groups with precursor or to arrest or slowing down of DNA synthesis sured from in vitro 3HTdR LIs and due to changing microenvironments. There has been recent had the longest latency period to evidence (Chaplin et al., 1987) Begg et al. (1985) and by White & Meistrich (1986) Wilson & McNally, unpublished observations) . In all but one of these cases the initial value of the R.M. was not significantly different from 0.5. For one tumour (SAF) it was closer to 0.4. Of course it has not been possible to make comparable measurements in human tumours.
A potential source of error in measuring the LI arises through cell division in the time between injecting the BrdUrd and taking the biopsy. The larger this time, the greater the error will be. We have made the simplest, and probably only technically feasible, correction of halving the number of BrdUrd labelled cells that appear in GI, as described above. Figure 10 shows the effect of not making this correction on both the LI (A) and Tpot (B). The number of tumours with a LI of greater than 10%, increased from 12 to 17 if the correction was not made and the number of with a Tpot of 5 days or less increased from 11 to 14. The greatest effect of not making the correction was in those tumours with the longest interval between injection and biopsy and in those which had a very short Ts. If the time interval is too short, however, it may be difficult to detect a significant movement of BrdUrd labelled cells towards G2. Based on these limited results, we feel that intervals of 3 to 4 h for melanomas and head and neck tumours, and between 6 to 8 h for other tumour types may be most suitable.
The technique we have used to measure Tpot is based on measurements from a single biopsy. It is important, therefore, to try and assess the potential error due to heterogeneity within individual tumours with respect to their cell kinetics. We have addressed this problem in four of the patients we have studied. There were no differences in the cell kinetic parameters measured in six samples from a nonHodgkin's lymphoma (Figure 8) or two biopsies from a SCC of the oesophagus (Figure 9 ). There were some variations in an aneuploid SCC of the cervix (patient B3, Figure 6 ). The greatest variation was in the total LI which varied from 4.3 to 7.3%. However, this was largely a reflection of variations in the extent of normal stromal tissue in each sample which were seen histologically and in the flow cytometer as variations in the fraction of the population that was hyperdiploid (Figure 6b ). When the potential doubling time was calculated excluding the 'normal' GI cells, there was relatively little variation from one sample to the next (mean Tpot 3.6 days, range 2.9 to 4.6 days, Figure 6f ). This example illustrates the importance of having parallel histology of tissue adjacent to pieces processed for FCM. Indeed, not only can the FCM analysis be related to the histology, but BrdUrd incorporation can also be assessed in the tissue section by immunohistochemical staining . In these three cases the main differences in cell kinetics from one sample to the next were in the LI with relatively small differences in the estimate of Ts. However, in the five samples from the recurrent carcinoma of the rectum (patient C4, Figure 7) , there was variation in both LI and Ts. In particular, the tissue taken from the polypoid fragment showed a much longer Ts (30.9h ) than the other four samples from the main bulk of the tumour which ranged from 13.2 to 19.3 h. The reason for this is unclear as there was no histological difference in the tumour from the two areas. These differences, in conjunction with variation in the LI (range 8.7 to 13.1%), resulted in a large range of Tpot throughout this tumour (3.4 to 9.8 days). Although parallel histology was not processed for each sample, the specimen was moderately differentiated and consisted of approximately 50% tumour cells and 50% normal stromal cells. It is possible that there were differences in the pattern of cellularity of each sample which could account tor the observed differences.
It would appear, from these four examples, that the principal source of variation between different samples is the LI. This, in turn, is reflected in relatively small variations in the estimated Tpot in all but one of the cases we have studied. Certainly, from a predictive point of view the variation we have measured would not be serious. If, for instance, patients were going to be selected for accelerated fractionation based on their kinetic parameters, one would not need to have a sharp delineation in the value of Tpot below which patients would be given the altered treatment and above which they would not. If a Tpot of 3.4 days was estimated and the true value was 7 days, the selection for accelerated fractionation would almost certainly not compromise the outcome (and vice versa).
The estimates of Tpot in this group of patients are striking because of the proportion of tumours which had the potential for rapid proliferation. Thirty-eight percent of the tumours in this study (from all the sites) had Tpots of less than 5 days. The shortest Tpot of 3.2 days was seen in a patient with metastatic oat cell carcinoma. Seven of the 16 patients with tumours of the head and neck, oesophagus or bronchus, sites accessible for biopsy and suitable for accelerated fractionation, had Tpots of less than 5 days. These estimates of Tpot are similar to the few that can be computed from the data collected by Steel (1977) .
Using the median Ts, the LI and a correction factor of 0.8, then the cases reported by Steel ranged from 1.3 days in a tumour of the maxillary antrum (Terz et al., 1971) to 11.7 days in a reticulum cell sarcoma (Peckham & Steel, 1972) . The study by Sakuma (1980) reports very short Tpots, in carcinoma of the oral cavity, ranging from 0.7 to 2 days. In radiotherapy, it has been calculated that if overall treatment times of 6 or 7 weeks are shortened to one half or one third by using 2 or 3 fractions per day then gains in local control can be achieved if the doubling time of clonogenic tumour cells is 5 days or shorter (Thames et al., 1983) . The rationale behind this approach is that if tumours are repopulating rapidly, then reducing the overall treatment, for instance by 21 days, will save 4.2 cell doublings in tumours with clonogenic doubling times of 5 days or less. This corresponds to a factor of 18 decrease in the number of cells which have to be killed by the treatment.
For patients to benefit from an altered treatment schedule, such as accelerated fractionation, it is important that cell kinetic information can be obtained with the minimum inconvenience to the patient and in a timescale useful to the clinician in selecting the appropriate treatment. The technique described here can obtain the relevant information within a day of biopsy without undue stress to the patient. The value of pretreatment cell kinetic measurements has yet to be verified in radiotherapy. Accelerated fractionation employing 3 treatments each day for a continuous period of 12 days is currently being employed at Mount Vernon Hospital to treat advanced head and neck and bronchial tumours (Saunders & Dische, 1986 ) with favourable regression and remission rates compared to previous studies. Whenever possible, patients receiving this treatment are now having their pretreatment cell kinetics measured. In future randomised controlled trials of accelerated fractionation, measurements of Tpot as we have described should be included in both arms of the trial. If it is shown that tumours with short potential doubling times are best treated in an accelerated course of radiotherapy, then there will be important implications, not only for the patients receiving radiotherapy but, also for those being managed by cytotoxic chemotherapy where rapid repopulation between cycles of treatment would have a similarly harmful influence upon tumour control, and measurements of Tpot should become part of the routine characterisation of the tumour before treatment. 
